| ²é¿´: 712 | »Ø¸´: 3 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
haioouͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
ÂÛÎÄÕªÒªÇëÇó·Ò룡
|
|
| Ä¿µÄ ²ÉÓÃMeta·ÖÎöµÄ·½·¨¶ÔÎÄÀ·¨ÐÁÖÎÁÆÒÖÓôÖ¢µÄÓÐЧÐÔ¼°°²È«ÐÔ½øÐÐϵͳµÄ·ÖÎö¡£·½·¨ ÀûÓüÆËã»úÊý¾Ý¿â·þÎñϵͳ£ºÖйúÖªÍøÈ«ÎÄÊý¾Ý¿â£¨CNKI£©¡¢ÖйúάÆÕÈ«ÎÄÊý¾Ý¿â£¨VIP£©¡¢ÖйúÉúÎïҽѧÎÄÏ×Êý¾Ý¿â£¨CMBdisc£©¡¢Íò·½È«ÎÄÊý¾Ý¿âºÍPubMedµÈ£¬¼ìË÷ʱÏÞΪ2005Äê-2015Ä꣬½üÊ®ÄêÓйØÎÄÀ·¨ÐÁÓëÆäËûÈκο¹ÒÖÓôÒ©Îïµ¥ÓõIJÉÓÃËæ»ú¶ÔÕյķ½·¨½øÐÐÁÆÐ§Óë²»Á¼·´Ó¦·ÖÎöµÄÎÄÏ×£¬Ñϸñ°´Õղο¼ÎÄÏ×µÄÄÉÈëºÍÅųý±ê×¼£¬ÒÔ¼°²ÉÓÃJadadÆÀ·Ö±ê×¼½øÐÐÆÀ·Ö£¬É¸Ñ¡¸ßÖÊÁ¿µÄÖÐÓ¢ÎÄÎÄÏ×£¬²¢¶ÔÆäʵÑéÊý¾Ý½øÐÐÊÕ¼¯×ܽᣬ²ÉÓÃRevMan5.0Èí¼þ½øÐÐMeta·ÖÎö¡£½á¹û ×îÖÕÄÉÈë25ÏîËæ»ú¶ÔÕÕÑо¿£¬°üÀ¨ÖÐÎÄÑо¿22ÏӢÎÄÑо¿6Ï¶ÔÖÐÎÄÎÄÏ×ÎÄÀ·¨ÐÁÖÎÁÆÒÖÓôÖ¢½øÐÐÓÐЧÐÔÆÀ¼Û£¬½á¹ûÏÔʾÎÄÀ·¨ÐÁÓÅÓÚÆäËû¿¹ÒÖÓôÒ©ÎÇÒ½á¹û¾ßÓÐͳ¼ÆÑ§ÒâÒ壻¶ÔÓ¢ÎÄÎÄÏ×·ÖÎö½á¹ûÒÀÈ»ÏÔʾÎÄÀ·¨ÐÁÓÅÓÚÆäËûÒ©ÎÇÒ½á¹û¾ßÓÐͳ¼ÆÑ§ÒâÒ壻×ÛºÏÖÐÓ¢ÎÄÎÄÏ×½á¹ûÓëÖÐÓ¢ÎĶÀ×Ô·ÖÎö½á¹ûÒ»Ö£¬¾ßÓÐͳ¼ÆÑ§ÒâÒå¡£¸ù¾Ý¶Ô°²È«ÐÔµÄMeta·ÖÎöµÄ½á¹ûÏÔʾ£¬³£¼û֢״ΪÌåÖØÔö¼Ó¡¢ÊÓÎïÄ£ºý¡¢±ãÃØ¡¢Ð͝¹ýËÙ¡¢ÐĵçͼÒì³£¡¢Æ£±¹¡¢Âö²«¿ì¡¢È«Éí²»ÊʵIJ»Á¼·´Ó¦µÄºÏ²¢Ð§Ó¦½á¹ûpÖµ¶¼Ð¡ÓÚ0.05£¬RR<1£¬ÉÁÖͼÖÐÏÔʾ£¬ÁâÐÎͼ°¸Î»ÓÚ´¹Ö±ÏßµÄ×ó²à£¬ÇÒÓëÎÞЧÏßÏà·ÖÀë¡£µ«¶ÔÓÚÐļ¡¢¶ñÐĺÍʳÓûϽµ£¬ÎÄÀ·¨ÐÁ×é±ÈÆäËû³£Óÿ¹ÒÖÓôÒ©ÎïÑÏÖØ¡£×ÜÌå·ÖÎö¶ÔÓڱȽϳ£¼ûµÄ²»Á¼·´Ó¦£¬·þÓÃÎÄÀ·¨ÐÁ±ÈÆäËû³£Óÿ¹ÒÖÓôÒ©ÎïËù²úÉúµÄ²»Á¼·´Ó¦½ÏÇᣬÏà¶Ô±È½Ï°²È«£¬½áÂÛ ÎÄÀ·¨ÐÁ¶Ô±ÈÆäËû¿¹ÒÖÓôÒ©ÎïÁÆÐ§¸üºÃ£¬¸ü¼Ó°²È«¿É¿¿¡£ |
» ²ÂÄãϲ»¶
283·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
349Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
296²ÄÁÏר˶Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ
ÒѾÓÐ7È˻ظ´
²ÄÁÏ340·Öµ÷¼Á
ÒѾÓÐ8È˻ظ´
316Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
315Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
330·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
»¯¹¤µ÷¼Á303·Ö£¬¹ýËļ¶
ÒѾÓÐ9È˻ظ´

²Ó²ÓÃÃ
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 68
- Ó¦Öú: 135 (¸ßÖÐÉú)
- ¹ó±ö: 1.097
- ½ð±Ò: 14467.1
- É¢½ð: 3921
- ºì»¨: 102
- ɳ·¢: 3
- Ìû×Ó: 2121
- ÔÚÏß: 396.8Сʱ
- ³æºÅ: 1783324
- ×¢²á: 2012-04-27
- ÐÔ±ð: GG
- רҵ: »·¾³¹¤³Ì

2Â¥2015-05-20 16:01:50
²Ó²ÓÃÃ
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 68
- Ó¦Öú: 135 (¸ßÖÐÉú)
- ¹ó±ö: 1.097
- ½ð±Ò: 14467.1
- É¢½ð: 3921
- ºì»¨: 102
- ɳ·¢: 3
- Ìû×Ó: 2121
- ÔÚÏß: 396.8Сʱ
- ³æºÅ: 1783324
- ×¢²á: 2012-04-27
- ÐÔ±ð: GG
- רҵ: »·¾³¹¤³Ì
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
Ä¿µÄ ²ÉÓÃMeta·ÖÎöµÄ·½·¨¶ÔÎÄÀ·¨ÐÁÖÎÁÆÒÖÓôÖ¢µÄÓÐЧÐÔ¼°°²È«ÐÔ½øÐÐϵͳµÄ·ÖÎö¡£ Purpose The efficacy and safety of venlafaxine in the treatment of depression were analyzed systematically based on Meta analysis method. ·½·¨ ÀûÓüÆËã»úÊý¾Ý¿â·þÎñϵͳ£ºÖйúÖªÍøÈ«ÎÄÊý¾Ý¿â£¨CNKI£©¡¢ÖйúάÆÕÈ«ÎÄÊý¾Ý¿â£¨VIP£©¡¢ÖйúÉúÎïҽѧÎÄÏ×Êý¾Ý¿â£¨CMBdisc£©¡¢Íò·½È«ÎÄÊý¾Ý¿âºÍPubMedµÈ£¬¼ìË÷ʱÏÞΪ2005Äê-2015Ä꣬½üÊ®ÄêÓйØÎÄÀ·¨ÐÁÓëÆäËûÈκο¹ÒÖÓôÒ©Îïµ¥ÓõIJÉÓÃËæ»ú¶ÔÕյķ½·¨½øÐÐÁÆÐ§Óë²»Á¼·´Ó¦·ÖÎöµÄÎÄÏ×£¬Ñϸñ°´Õղο¼ÎÄÏ×µÄÄÉÈëºÍÅųý±ê×¼£¬ÒÔ¼°²ÉÓÃJadadÆÀ·Ö±ê×¼½øÐÐÆÀ·Ö£¬É¸Ñ¡¸ßÖÊÁ¿µÄÖÐÓ¢ÎÄÎÄÏ×£¬²¢¶ÔÆäʵÑéÊý¾Ý½øÐÐÊÕ¼¯×ܽᣬ²ÉÓÃRevMan5.0Èí¼þ½øÐÐMeta·ÖÎö¡£ Method For collecting and summarizing the experimental datas of both English and Chinese literatures with high-quality, which were scored by using Jadad grade standard and strictly following the integration and elimination standard of literature , the computer database service systems, such as CNKI, VIP,CMBdisc, Wan- fang database and PubMed, were used to search literatures in the past decade(namely, retrieval time limitation was 2005-2015 ) that were related to venlafaxine and other anti-depression medication to random contrastive analyze the curative effects and adverse reactions of its alone use. And the experimental datas were analyzed with Meta based on RevMan5.0 software. ½á¹û ×îÖÕÄÉÈë25ÏîËæ»ú¶ÔÕÕÑо¿£¬°üÀ¨ÖÐÎÄÑо¿22ÏӢÎÄÑо¿6Ï¶ÔÖÐÎÄÎÄÏ×ÎÄÀ·¨ÐÁÖÎÁÆÒÖÓôÖ¢½øÐÐÓÐЧÐÔÆÀ¼Û£¬½á¹ûÏÔʾÎÄÀ·¨ÐÁÓÅÓÚÆäËû¿¹ÒÖÓôÒ©ÎÇÒ½á¹û¾ßÓÐͳ¼ÆÑ§ÒâÒ壻¶ÔÓ¢ÎÄÎÄÏ×·ÖÎö½á¹ûÒÀÈ»ÏÔʾÎÄÀ·¨ÐÁÓÅÓÚÆäËûÒ©ÎÇÒ½á¹û¾ßÓÐͳ¼ÆÑ§ÒâÒ壻×ÛºÏÖÐÓ¢ÎÄÎÄÏ×½á¹ûÓëÖÐÓ¢ÎĶÀ×Ô·ÖÎö½á¹ûÒ»Ö£¬¾ßÓÐͳ¼ÆÑ§ÒâÒå¡£ Results 25 randomized controlled studies were identified finally, including 22 China studies and 6 English studies. The results of the effectiveness integrated evaluation of Chinese literatures about venlafaxine in the treatment of depression showed that venlafaxine was superior to other anti-depression medication, which indicated it has statistical significance. The same results were also obtianed by the analysis of English literatures. Combine the results of both Chinese and English literatures, it was proved to has statistical significance. |

3Â¥2015-05-20 16:56:32
²Ó²ÓÃÃ
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 68
- Ó¦Öú: 135 (¸ßÖÐÉú)
- ¹ó±ö: 1.097
- ½ð±Ò: 14467.1
- É¢½ð: 3921
- ºì»¨: 102
- ɳ·¢: 3
- Ìû×Ó: 2121
- ÔÚÏß: 396.8Сʱ
- ³æºÅ: 1783324
- ×¢²á: 2012-04-27
- ÐÔ±ð: GG
- רҵ: »·¾³¹¤³Ì
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
haioou: ½ð±Ò+40, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2015-05-23 14:42:57
haioou: ½ð±Ò+40, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2015-05-23 14:42:57
|
¸ù¾Ý¶Ô°²È«ÐÔµÄMeta·ÖÎöµÄ½á¹ûÏÔʾ£¬³£¼û֢״ΪÌåÖØÔö¼Ó¡¢ÊÓÎïÄ£ºý¡¢±ãÃØ¡¢Ð͝¹ýËÙ¡¢ÐĵçͼÒì³£¡¢Æ£±¹¡¢Âö²«¿ì¡¢È«Éí²»ÊʵIJ»Á¼·´Ó¦µÄºÏ²¢Ð§Ó¦½á¹ûpÖµ¶¼Ð¡ÓÚ0.05£¬RR<1£¬ÉÁÖͼÖÐÏÔʾ£¬ÁâÐÎͼ°¸Î»ÓÚ´¹Ö±ÏßµÄ×ó²à£¬ÇÒÓëÎÞЧÏßÏà·ÖÀë¡£µ«¶ÔÓÚÐļ¡¢¶ñÐĺÍʳÓûϽµ£¬ÎÄÀ·¨ÐÁ×é±ÈÆäËû³£Óÿ¹ÒÖÓôÒ©ÎïÑÏÖØ¡£ The security Meta analysis showed that the common clinical symptoms were weight gain, blurred vision,constipation,tachycardia, electrocardiographic abnormality, exhaustion,rapid pulse and general malaise, the P values of merged effect of those symptoms were less than 0.05£¬RR<1. The forest graph showed that diamond pattern was located at the left side of perpendicular line, separated with invalid line phase. compared with other anti-depression medication, venlafaxine has more serious bad reaction to palpitation, nausea and appetite degression. ×ÜÌå·ÖÎö¶ÔÓڱȽϳ£¼ûµÄ²»Á¼·´Ó¦£¬·þÓÃÎÄÀ·¨ÐÁ±ÈÆäËû³£Óÿ¹ÒÖÓôÒ©ÎïËù²úÉúµÄ²»Á¼·´Ó¦½ÏÇᣬÏà¶Ô±È½Ï°²È«£¬½áÂÛ ÎÄÀ·¨ÐÁ¶Ô±ÈÆäËû¿¹ÒÖÓôÒ©ÎïÁÆÐ§¸üºÃ£¬¸ü¼Ó°²È«¿É¿¿¡£ The overall analysis of common adverse reactions showed that venlafaxine was relatively safe with adverse reaction were slighter, compared with other anti-depression medication. Conclusion venlafaxine has better efficacy and more safe and reliable compared with other anti-depression medication. |

4Â¥2015-05-20 17:30:32














»Ø¸´´ËÂ¥